1. Home
  2. NHI vs LQDA Comparison

NHI vs LQDA Comparison

Compare NHI & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National Health Investors Inc.

NHI

National Health Investors Inc.

HOLD

Current Price

$82.76

Market Cap

3.9B

Sector

Real Estate

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$43.39

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NHI
LQDA
Founded
1991
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.1B
IPO Year
1991
2018

Fundamental Metrics

Financial Performance
Metric
NHI
LQDA
Price
$82.76
$43.39
Analyst Decision
Buy
Strong Buy
Analyst Count
5
10
Target Price
$85.20
$38.60
AVG Volume (30 Days)
207.6K
2.3M
Earning Date
02-26-2026
03-18-2026
Dividend Yield
4.54%
N/A
EPS Growth
8.88
N/A
EPS
3.17
N/A
Revenue
$357,572,000.00
$69,216,000.00
Revenue This Year
$7.18
$993.31
Revenue Next Year
$14.87
$219.14
P/E Ratio
$25.60
N/A
Revenue Growth
8.40
343.41
52 Week Low
$65.23
$11.26
52 Week High
$82.39
$46.67

Technical Indicators

Market Signals
Indicator
NHI
LQDA
Relative Strength Index (RSI) 62.22 61.82
Support Level $78.73 $41.09
Resistance Level $82.39 $46.67
Average True Range (ATR) 1.96 2.63
MACD 0.24 0.31
Stochastic Oscillator 96.16 68.29

Price Performance

Historical Comparison
NHI
LQDA

About NHI National Health Investors Inc.

National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: